Philippe Eugster

Philippe Eugster

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Journal of Chromatography A
Verified
Journal Article
Closed access
CFCristiano S. Funari
Cristiano S. Funari
PEPhilippe Eugster
Philippe Eugster
SMSophie Martel
Sophie Martel
PCPierre-Alain Carrupt
Pierre-Alain Carrupt
JWJean-Luc Wolfender
Jean-Luc Wolfender
DSDulce Helena Silva
Dulce Helena Silva

1 December 2014 in Phytochemistry
Verified
Journal Article
Closed access
PEPhilippe Eugster
Philippe Eugster
JBJulien Boccard
Julien Boccard
BDBenjamin Debrus
Benjamin Debrus
LBLise Bréant
Lise Bréant
JWJean-Luc Wolfender
Jean-Luc Wolfender
PCPierre-Alain Carrupt
Pierre-Alain Carrupt

1 October 2013 in Journal of Chromatography A
Verified
Journal Article
Closed access
DSDany Spaggiari
Dany Spaggiari
SFSzabolcs Fekete
Szabolcs Fekete
PEPhilippe Eugster
Philippe Eugster
JVJean-Luc Veuthey
Jean-Luc Veuthey
LGLaurent Geiser
Laurent Geiser
DGDavy Guillarme
Davy Guillarme

1 October 2012 in Journal of Chromatography A
Verified
Journal Article
Closed access
PEPhilippe Eugster
Philippe Eugster
DBDaniel Biass
Daniel Biass
DGDavy Guillarme
Davy Guillarme
PFPhilippe Favreau
Philippe Favreau
RSReto Stöcklin
Reto Stöcklin
JWJean-Luc Wolfender
Jean-Luc Wolfender

1 September 2018 in Hypertension
Verified
Journal Article
Closed access
PDF file
SHScott A. Hubers
Scott A. Hubers
JWJessica R. Wilson
Jessica R. Wilson
CYChang Yu
Chang Yu
HNHui Nian
Hui Nian
EGEric Grouzmann
Eric Grouzmann
NBNancy J. Brown
Nancy J. Brown
DPP (dipeptidyl peptidase)-4 inhibitors are antidiabetic drugs that may increase heart failure in high-risk patients. NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3–36) in vitro. NPY (3–36) decreases release of norepinephrine via the Y2 receptor. We tested the hypothesis that DPP4 inhibition would potentiate the vasoconstrictor effect of NPY. Eighteen nonsmokers (12 healthy controls and 6 with type 2 diabetes mellitus) participated in 1 of 2 randomized, double-blind, placebo-controlled crossover studies. First, subjects were randomized to order of treatment with sitagliptin 100 mg/d versus placebo for 7 days separated by 4-week washout. On the last day of treatment, NPY was infused by brachial artery and forearm blood flow was measured using plethysmography. Blood samples were collected after each dose. NPY infusions were repeated after 90-minute washout and intra-arterial enalaprilat. Second, 5 healthy subjects were randomized to crossover treatment with sitagliptin 100 mg/d plus valsartan 160 mg/d versus placebo plus valsartan. NPY infusions were performed on the seventh day of treatment. NPY caused dose-dependent vasoconstriction. During enalaprilat, sitagliptin significantly potentiated NPY-induced vasoconstriction in controls and diabetics (P≤0.02 for forearm blood flow in either group). Baseline norepinephrine release was increased during sitagliptin and enalaprilat, but not further by NPY. Sitagliptin increased the ratio of NPY to NPY (3–36). During valsartan, sitagliptin also significantly potentiated NPY-induced vasoconstriction (P=0.009 for forearm blood flow). Potentiation of endogenous NPY could contribute to cardiovascular effects of DPP4 inhibitors in patients taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

10 August 2022 in Clinica Chimica Acta
Verified
Journal Article
Open access
PEPhilippe Eugster
Philippe Eugster
MDMarielle Dunand
Marielle Dunand
BGBaptiste Grund
Baptiste Grund
AIAnton Ivanyuk
Anton Ivanyuk
NSNathalie Fogarasi Szabo
Nathalie Fogarasi Szabo
HCHaithem Chtioui
Haithem Chtioui
Serotonin is transformed into melatonin under the control of the light/dark cycle, representing a cornerstone of circadian rhythmicity. Serotonin also undergoes extensive metabolism to produce 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for the diagnosis and monitoring of serotonin secreting neuroendocrine tumors (NETs). While serotonin, melatonin and their metabolites are part of an integrated comprehensive system, human observations about their respective plasma concentrations are still limited. We report here for the first time a multiplex UHPLC-MS/MS assay for the quantification of serotonin, 5-HIAA, 5-hydroxytryptophol (5-HTPL), N-acetyl-serotonin (NAS), Mel, 6-OH-Mel, 5-methoxytryptamine (5-MT), 5-methoxytryptophol (5-MTPL), and 5-methoxyindoleacetic acid (5-MIAA) in human plasma. Analytes were extracted by protein precipitation and solid phase extraction. Plasma concentrations for these analytes were determined in 102 healthy volunteers. The LLOQ of the assay ranges from 2.2 nM for serotonin to 1.0 pM for 6-OH-Mel. This sensitivity enables the quantification of circulating serotonin, 5-HIAA, NAS, Mel, and 5-MIAA, even at their lowest diurnal concentrations. This assay will enable specific, precise and accurate measurement of serotonin, Mel and their metabolites to draw a detailed picture of this complex pineal metabolism, allowing a dynamic understanding of these pathways and providing promising biomarkers and a metabolic signature for serotonin-secreting NETs.